P3.01-15 Efficacy of Paclitaxel Plus TS1 Against Non-Small Cell Lung Cancer Previously Treated

Abstract

Salvage chemotherapy is frequently used. However, the efficacy of salvage chemotherapy of paclitaxel plus TS1 (TTS1) is still unknown. We retrospectively reviewed the chart records of our non-small cell lung cancer patients who were treated between 2010 and 2013. Clinical characteristics, type of tumor EGFR mutation, response to first-line EGFR-TKI treatment or not, and efficacies of TTS1, were collected. Total 25 patients were enrolled in this study. No patients archived complete response and six patients had partial response (ORR: 24%). The disease control rate was 60% (15/25). The progression free survival (PFS) was 4.8 months and overall survival (OS) was 12.4 months. Among these 25 patients that received TTS1, 17 of them had driver mutations. Patients with driver mutations had better PFS (4.9 months vs 1.8 months) and OS (15.5 months vs 7.2 months) compared with those without driver mutations. TTS1 are effective salvage chemotherapeutic agents, especially in tumor EGFR mutated patients. Paclitaxel plus TS1 is another treatment of choice for NSCLC patients before a more efficient salvage treatment strategy is found.